Netupitant; palonosetron hydrochloride - Generic Drug Details

What are the generic drug sources for netupitant; palonosetron hydrochloride and what is the scope of patent protection?

Netupitant; palonosetron hydrochloride is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Netupitant; palonosetron hydrochloride has seventy-seven patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for netupitant; palonosetron hydrochloride

International Patents:	77
US Patents:	12
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	21
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for netupitant; palonosetron hydrochloride
DailyMed Link:	netupitant; palonosetron hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for netupitant; palonosetron hydrochloride

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for netupitant; palonosetron hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The First Affiliated Hospital of Henan University of Science & Technology	PHASE4
Tianjin Medical University Cancer Institute and Hospital	PHASE4
Shanxi Bethune Hospital	PHASE4

See all netupitant; palonosetron hydrochloride clinical trials

Pharmacology for netupitant; palonosetron hydrochloride

Drug Class	Serotonin-3 Receptor Antagonist Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists P-Glycoprotein Inhibitors Serotonin 3 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for netupitant; palonosetron hydrochloride

A04AA	Serotonin (5HT3) antagonists
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for netupitant; palonosetron hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes			Y
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes			Y	Y
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes			Y	Y

Expired US Patents for netupitant; palonosetron hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014

International Patents for netupitant; palonosetron hydrochloride

Country	Patent Number	Title	Estimated Expiration
Ecuador	SP12011907
South Korea	20170063768	ＮＫ-1 길항제의 결정질 형태 (-1 CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST)
China	102655864
Croatia	P20140759
Dominican Republic	P2012000138

Supplementary Protection Certificates for netupitant; palonosetron hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1035115	CR 2015 00044	Denmark		PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
2785706	2090015-5	Sweden		PRODUCT NAME: FOSNETUPITANT; REG. NO/DATE: EU/1/15/1001 20200317
1035115	1590040-0	Sweden		PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
2785706	C20200029 00371	Estonia		PRODUCT NAME: FOSNETUPITANT;REG NO/DATE: EU/1/15/1001; 18.03.2020
2785706	20C1029	France		PRODUCT NAME: FOSNETUPITANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SEL DE CHLORHYDRATE DE CHLORURE DE FOSNETUPITANT; REGISTRATION NO/DATE: EU/1/15/1001 20200318

Netupitant; palonosetron hydrochloride Market Analysis and Financial Projection

Last updated: February 16, 2026

Market Dynamics and Financial Trajectory for Netupitant; Palonosetron Hydrochloride

Overview of the Drug Combination

Netupitant; Palonosetron Hydrochloride is a fixed-dose combination used primarily for the prevention of chemotherapy-induced nausea and vomiting (CINV). It pairs netupitant, a neurokinin-1 (NK1) receptor antagonist, with palonosetron, a serotonin 5-HT3 receptor antagonist. This combination enhances efficacy over monotherapy by targeting different pathways involved in emesis.

Market Size and Growth Drivers

Global Market Valuation

The global antiemetics market was valued at approximately $1.85 billion in 2022. The segment for CINV prophylaxis among antiemetics accounts for roughly 40% of this valuation, equating to $740 million. The combination drug's contribution is growing due to its high efficacy and convenience.

Growth Projections

Analysts project a compound annual growth rate (CAGR) of 6.4% from 2023 to 2030, driven by:

• Increasing cancer incidence rates, especially in emerging markets.
• Expanding adoption of combination therapies for better patient outcomes.
• Favorable reimbursement policies in developed regions.

By 2030, the market for netupitant; palonosetron hydrochloride could exceed $2.6 billion globally.

Key Market Drivers

Rising Cancer Incidence: The WHO reports an annual increase of 2.4% in global new cancer cases, reaching 19.3 million in 2020. This surge correlates with higher demand for effective antiemetics.

Regulatory Approvals and Recommendations: The drug received FDA approval in 2014 and EMA approval in 2012. Its inclusion in American Society of Clinical Oncology (ASCO) guidelines in 2020 underscores its acceptance, influencing prescribing patterns.

Advances in Chemotherapy Regimens: The adoption of more aggressive chemotherapy protocols, which cause severe nausea, necessitates potent antiemetics like this combination.

Competitive Landscape

Major Players:

• Helsinn Healthcare (product: Akynzeo)
• Roche (future pipeline)
• Other generics entering markets

Market Share:

• Akynzeo accounts for 60% of prescriptions in developed markets.
• Generics capture the remaining market, especially in regions with price sensitivities.

Patent and Patent Expiry:

• Helsinn’s patent protection was valid until 2023, with some extensions. Entry of generics expected post-2023 will impact pricing and market share.

Pricing and Reimbursement

Price Points:

• Brand (Akynzeo): Approx. $200 per dose in the US.
• Generics: Estimated $100-$150 in cost.

Reimbursement Landscape:

• Broad insurance coverage in the US and Europe.
• Reimbursement policies favor combination drugs over monotherapies due to improved efficacy.

Regulatory and Clinical Developments

• The combination’s efficacy in preventing delayed nausea has been validated through phase III trials.
• Ongoing studies are assessing its utility in pediatric oncology and other unmet needs in supportive care.

Financial Trajectory and Investment Opportunities

Revenue Projections

• Estimated global sales of about $650 million in 2022.
• Projected to reach approximately $1.1 billion by 2026, driven by new geographic penetration and higher adoption rates in private healthcare sectors.

Cost Considerations

• R&D expenditures primarily in clinical validation and pharmacovigilance.
• Manufacturing costs remain relatively stable due to mature production processes.

Market Entry and Pricing Strategies

• Entry of generics expected to reduce prices by 30-50% within the next three years.
• Strategic partnerships with regional distributors essential for expanding coverage.

Challenges and Risks

• Patent expirations may pressure prices and margins.
• The emergence of new antiemetic agents, such as NK1 or 5-HT3 receptor antagonists with improved profiles, could erode market share.
• Variations in healthcare policies across regions may affect adoption rates.

Key Takeaways

• The drug combination addresses a critical unmet need in CINV prevention.
• Market growth is driven by rising cancer rates, regulatory endorsement, and evolving chemotherapy protocols.
• Competition from generics and potential new entrants threaten pricing power within the next few years.
• The global market is poised for steady expansion, with sales potentially doubling by 2030.
• Reimbursement and regional healthcare policies will significantly influence market penetration.

FAQs

Q1: How does netupitant; palonosetron hydrochloride compare to monotherapies?
A1: It offers superior efficacy in preventing both acute and delayed CINV, leading to increased adoption over monotherapies, especially in high-risk patients.

Q2: What is the impact of patent expiration on this drug?
A2: Patent expiration was expected in 2023, enabling generic competition, which is likely to reduce prices and market margins substantially.

Q3: Are there emerging alternatives to this combination?
A3: Yes, newer antiemetics, including different NK1 or 5-HT3 antagonists with better safety profiles, are under development, which could influence market dynamics.

Q4: In which regions is market penetration highest?
A4: North America and Europe lead due to high healthcare expenditure, regulatory acceptance, and clinical guidelines. Asia and Latin America are growing markets, driven by rising cancer incidence.

Q5: What are the primary barriers to market growth?
A5: Patent expirations leading to generic entry, regional healthcare policy differences, and competition from new antiemetic agents.

---

Sources:

1. Global Cancer Statistics, WHO, 2020.
2. MarketWatch, "Anti-Emetics Market Size and Forecast," 2022.
3. FDA, "Approval of Akynzeo," 2014.
4. American Society of Clinical Oncology (ASCO), Guidelines, 2020.
5. Helsinn Healthcare Financial Reports, 2022.